Technical Memorandum

TO: Physicians, Staff

From: Wesley Kim, MD, Medical Director

Date: April 11, 2014

Subject: Ceruloplasmin

Beginning May 5, 2014, DLS will be changing the methodology for Ceruloplasmin testing from the Quest Roche Integra platform to the Roche c502 immunoturbidimetric method. This change allows DLS to offer the testing in-house, at its central reference lab facility rather than having it sent to the mainland, thus improving turn-around time for test results.

Compared to the current method at Quest, the new method does show a slight negative bias and the new reference ranges for both male and female are slightly lower (see table below). However, based on a comprehensive comparison study between the two methods, greater than 95% of the patients studied showed good correlation from low, normal and high qualitative flagging classification.

Test Information:

TEST	ORDER CODE	OLD REFERENCE RANGE	NEW REFERENCE RANGE	UNITS
Ceruloplasmin	4060	Male: 18 - 36 Female: 18 - 53	Male : 15 - 30 Female : 16 - 45	mg/dL

Because there is always some variation in numerical values when changing methods, it is recommended to re-baseline your patients, if you are monitoring ceruloplasmin levels, with the new assay before making therapeutic decisions based on the new assay results, if clinically indicated.

If you have any questions please call client services at 589-5101 or Dr. Wesley Kim at 589-5131.